Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP104 in SLE-Associated Thrombotic Microangiopathy
NCT05504187Phase 2Not yet recruiting
- Sponsor
- Kira Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of KP104 in systemic lupus erythematosus (SLE), thrombotic microangiopathy (TMA), sponsored by Kira Pharmaceuticals. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
KP104
03
Conditions
systemic lupus erythematosus (SLE)thrombotic microangiopathy (TMA)
Beyond the preview
Go deeper on NCT05504187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504187.